DOXORUBICIN HCl, pegylated liposomal, 2mg/ml, 10ml vial
Valid Article
DOXORUBICIN pegylated liposomal
- In the WHO list of Essential Medicines 2023 (Complementary List)
Therapeutic Action
Anthracycline cytotoxic
Doxorubicin hydrochloride encapsulated in liposomes with methoxypolyethylene glycol (MPEG) on the surface. This process is known as pegylation and protects the liposomes from detection by the mononuclear phagocytic system (MPS), thereby increasing their duration in the blood.
Indications
Ovarian cancer
Kaposi's sarcoma in HIV patients
Instructions for use
Must be given as IV infusion in 5% dextrose, via the tubing of an IV infusion dedicated to doxorubicin.
Ensure that the doxorubicin is administered intravenously into a large vein to minimise the risk of thrombosis or perivenous extravasation (risk of necrosis of surrounding tissue).
Precautions for Use
Do not mix with heparin (risk of precipitate).
Contraindicated during pregnancy.
Advise women of childbearing age to use effective contraception during treatment with doxorubicin and for 6 months after the last dose.
- Dangerous substance for the staff handling it.
- Cytotoxic drugs should not be handled or administered by pregnant staff members.
- It is mandatory to train the staff and to follow the Standard Precautions during preparation, reconstitution, dispensation, stock management and disposal : wear gloves, gown with long sleeves, protective glasses, respirator, etc.
(See introduction: Cytotoxic drugs in the MSF Supply Chain)
Storage
- Keep refrigerated between 2ºC and 8ºC - Protect from sunlight
- Do not freeze.
- Shelf life: 18 months
- Any unused solution should be discarded.